Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FHD 609

Next Previous
X
Search
Drug Profile

FHD 609

Alternative Names: FHD-609

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foghorn Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD9 protein degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Synovial sarcoma

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Synovial-sarcoma(In adolescents, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV)
  • 25 Apr 2024 Foghorn Therapeutics terminates a phase-I trial in Synovial sarcoma (In adolescents, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA, Spain, Italy, France (IV) due to sponsor decision (NCT04965753)
  • 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Synovial sarcoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top